Generic Semaglutide: Lower-Cost Semaglutide is Here!
BUY NOW
We Ship To The U.S. Only
Generic Semaglutide: Lower-Cost Semaglutide is Here!
We Ship To The U.S. Only
The Retatrutide Dosage Chart: A Comprehensive Guide On Dosage
- Posted On:
- 25 Jun, 2026
- 15 min read
-
Ozempic (Semaglutide): Once-weekly injectable for adults with type 2 diabetes or weight management.Starting From $329.99 -
Mounjaro (Tirzepatide): A once-weekly injectable medication for adults with type 2 diabetes or obesity.Starting From $559.99
10% Off On Your First Order
Click on the Copy Code button to copy your code.
No Expiry
Exclusive On Duty Free Meds Only
- Ozempic (Semaglutide): Once-weekly injectable for adults with type 2 diabetes or weight management.Starting From $329.99
- Mounjaro (Tirzepatide): A once-weekly injectable medication for adults with type 2 diabetes or obesity.Starting From $559.99
10% Off On Your First Order
Click on the Copy Code button to copy your code.
No Expiry
Exclusive On Duty Free Meds Only
- Retatrutide is a next-generation triple-agonist medication
- It is currently being studied in Phase 3 trials for use in obesity and metabolic condition treatment
- This medication has yet to get official FDA approval and be released
- It is important that patients planning to use the medication understand the correct dosing associated with the medication to minimize the risk of things like GI side effects
- All of the following information surrounding this upcoming medication is based on what has been studied in clinical trials so far
Note: This guide is not a substitute for professional medical advice. Dosing and titration may change after Phase 3 data is published.
Retatrutide Dosage Chart (Week-by-Week Dosing Schedule Breakdown)
The following chart is based on data from the first two phases of clinical trials since the drug has not yet been officially approved with specific dosing. These doses have not yet been officially approved.
This medication is still in Phase 3 trials – although results may be released ahead of the original February 2026 timeline – and dosing may change upon release. The doses of this medication are usually escalated once patients have been on a dose for about four weeks. There may also be additional adjustments made based on the patient’s tolerability of the medication. Long-term safety data are still under evaluation – especially concerning glucagon receptor activation. This medication may be approved and released as early as within the next couple of years.
| Phase | Weeks | Weekly Dose | Dose Level | Phase Goals |
| Initiation Phase | Weeks 1-4 | 2 mg | Start dose (lowest dose) | Allow the body to adjust… |
| First Escalation | Weeks 5-8 | 4 mg | Increase to next dose level |
|
| Second Escalation | Weeks 9-12 | 8 mg | Step up again if tolerated | Improve weight-loss… |
| Third (Optional) Escalation | Weeks 13-16 | 12 mg | Optional increase | Reach higher maintenance… |
| Maintenance Phase | Week 17+ | Highest tolerated dose | Highest well-tolerated dose | Long-term control |
What Is Retatrutide?
Retatrutide is a triple mechanism medication – a GLP-1, GIP, and glucagon receptor agonist – that is f for its effects in supporting weight loss in patients struggling with obesity and treatment for issues like diabetes or pre-diabetes. The GLP-1 part of the medication helps with appetite suppression and delays gastric emptying. The GIP part of the medication improves the patient’s insulin response and may synergize with the GLP-1 component. Activation of the glucagon receptor boosts how much energy the body burns. Retatrutide medication has not yet been approved and is only available to patients in clinical trials at this time. However, early results from these trials have shown this medication to be highly effective for weight loss and have created a big interest in what dosing schedules and escalation strategies will look like when the medication is released.
How Does Retatrutide Dosing Work?
Retatrutide is given as a weekly injection – like how other GLP-1-based therapies are usually dosed. Patients usually start by taking a lower dose (often 2 mg) of the medication and having this dose gradually increased as the body gets used to it to make sure it is tolerated. Patients should make sure they are following the instructions on titration given to them by their physician due to the medication’s potency and to reduce the chances of GI side effects (which often occur with these types of medications).
How Much Weight Loss Patients Can Expect At Each Dose
Exact weight loss percentages differ between patients depending on factors such as baseline body weight and adherence to their dosing schedule. It also may vary based on metabolic differences. Phase 2 trial results showed that even lower doses of the medication helped patients lose significant amounts of weight early on. Patients taking the 1 mg dose of the medication lost about 7.2% of their body weight and patients taking the 4 mg dose of the medication lost about 12.9% of their body weight in the first 24 weeks. Patients in the 8 mg and 12 mg groups lost an average of over 17% in this same time period.
The 1 mg dose group lost an average of 8.7% of their body weight after 48 weeks. Those in the 4 mg dose group lost an average of 17.1% of their body weight in this same time period. Increased doses were linked with more substantial drops in body weight. Patients using the highest doses of retatrutide – 8 mg and 12 mg – lost about 24% of their body weight after 48 weeks. These weight loss percentages reflect mean values and individual outcomes are not guaranteed.
The exact amount of weight patients can expect to lose while taking this medication depends on factors such as baseline weight and how well they are keeping up with their dosing schedule. Patients also usually lose more weight the longer they are on the medication. The exact amount of weight that will be lost while using the medication differs between patients and may vary from clinical data once the medication is approved for public use. Patients using this medication should also keep in mind that weight loss effects may plateau over time with extended use (based on GLP-1 class trends).
How Retatrutide Compares To Other Weight Loss Medications
Semaglutide (Wegovy/Ozempic) is a GLP‑1 receptor agonist that does not impact GIP or glucagon receptor activity. Tirzepatide (Mounjaro/Zepbound) produces its effects by activating the GIP and GLP-1 receptor pathways. Retatrutide engages both the GIP and GLP-1 pathways. However, this medication also impacts glucagon receptors. All of these medications come in the form of a weekly injection.
Each of these medications has also been shown to have varying effects on how much weight they help patients lose. Semaglutide often helps patients lose about 10% to 15% of their body weight. Tirzepatide is a little more effective for this – often helping patients lose 15% to 20% of their weight. Retatrutide may be the most effective of all of these medications for weight loss and has proven to help patients lose about 24% of their body weight in its highest doses. Tirzepatide may reach up to 22.5% weight loss according to SURMOUNT trials.
Semaglutide doses can be anywhere from 0.25 mg to 2.4 mg. The maximum doses are 2.4 mg for Wegovy users and up to 2 mg for Ozempic users. Tirzepatide is given in amounts of anywhere from 2.5 mg to 15 mg. This is closer to the 1 mg to 12 mg dosing range for retatrutide. However, retatrutide may be more potent at approved doses since it impacts more receptors.
Common Retatrutide Side Effects at Each Dose and How To Manage Them
| Common Side Effects | How to Manage Side Effects |
|
|
Missed Dose Instructions
A missed dose can still be taken as long as only a few days (within four days) have passed. Patients should skip the dose and proceed with the rest of the schedule as normal if it has been more than four days. They should never take more than one at once or take their medication earlier than it was scheduled for. Patients should contact their healthcare provider if they forget to take their medication for multiple weeks in a row. The patient’s tolerance may have changed if this is the case and a healthcare provider may have to readjust dosing.
Tips For Properly Injecting Retatrutide
- Retatrutide is a weekly injection that works like most other GLP-1 medications
- It can be injected into the abdomen or upper arm. It can also be injected into the thigh
- Injection sites should be rotated with each dose to avoid irritation
- Patients should also make sure to use the pen device provided for the medication and use it at the same time each week (the exact device/format may change by the time the medication is approved)
- Do not share pens
- Never inject into an irritated injection site
- Get training from a healthcare professional before administering the medication
- Clean the injection site with an alcohol swab
- Allow the medication to reach room temperature to reduce injection discomfort
Safety Reminder
Patients should never double their doses of this medication to make up for any doses that were missed. This medication should only be taken if remembered within four days of the missed dose. It should otherwise be skipped and the next dose in the schedule should be taken as usual. Any recurrent missed doses may require restarting the medication at a lower dose. Patients should also make sure to use the appropriate sharps container.
Who Should Use Retatrutide? (Based on Current Trial Criteria)
This medication is used in adult patients to help with obesity – or for patients who are overweight with a weight-related condition – and metabolic issues. This medication may not be a good fit for patients with a history of issues like pancreatitis or gallbladder problems. The same goes for those with a history of issues like thyroid cancer or heart rhythm problems. This medication is still not approved for use outside of the trials. This means eligibility may still change after regulatory review takes place. These medications also has not been proven safe for use in mothers who are pregnant or breastfeeding. People with severe GI motility disorders are usually not included in GLP-1 trials. Similar caution may be expected for retatrutide and patients with these issues may need to use this medication with caution or avoid it altogether.
Frequently Asked Questions
What is the initial dose for retatrutide treatment?
Most patients begin at 2 mg once weekly (based on what has been used in clinical trials). This lower starting point helps the body adjust and reduces the risk of early GI side effects.
Is it safe to change my dose on my own?
No. Retatrutide has a strong effect profile. Any changes to the dose should be guided by a healthcare professional (as increasing it too fast may cause unwanted side effects).
How long does titration take?
Escalations generally occur every four weeks in clinical trials. This may vary by patient and can change by the time the drug is officially approved.
When do results typically appear while taking retatrutide?
Many patients saw meaningful weight loss within the first 24 weeks in clinical studies. Results continue to build over time – especially at higher doses.
Can lower doses be continued over an extended period?
Yes. Some patients may remain on lower doses if they are effective and well-tolerated. Not everyone needs to escalate to higher doses.
How much weight loss occurs at the highest doses?
Trial participants treated with the 8 mg or 12 mg doses in Phase 2 studies lost nearly a quarter of their body weight over 48 weeks.
What are the differences between retatrutide and tirzepatide?
Tirzepatide activates the GIP and GLP-1 receptor pathways. Retatrutide activates GIP and GLP-1 receptors as well. However, it also targets the glucagon receptor. This third pathway may contribute to the higher levels of weight loss seen in early data.
Are retatrutide and Ozempic identical medications?
No. Ozempic (semaglutide) activates GLP-1 receptors only. Retatrutide has triple-agonist activity.
Will the dosing change once the drug is FDA-approved?
Possibly. Final dosing depends on outcomes from ongoing Phase 3 trials and FDA review.
Is retatrutide approved?
Not yet. It is currently in Phase 3 trials – with results expected before the originally projected 2026 timeline.
How can I get retatrutide safely?
Retatrutide is only accessible through clinical trials until it receives FDA approval. Patients should obtain it through a licensed pharmacy with a valid prescription once it becomes available.
The Bottom Line
Retatrutide uses a gradual weekly titration schedule to give the body time to adjust to the medication and create better/safer patient experiences. Final guidelines will be available after the medication is officially approved. Patients should speak with their healthcare provider for more personalized guidance.
Visit Duty Free Meds to get access to more affordable weight loss medication online from Canada.
Sources
Disclaimer: The information presented here is intended solely for educational purposes and should not be interpreted as medical advice, a diagnosis, or specific treatment recommendations. It does not imply endorsement of any particular medication or therapy. Health conditions and treatment responses can differ significantly between individuals; thus, this information is not a guarantee of safety, suitability, or effectiveness for anyone in particular. Always seek the guidance of a healthcare professional for personalized medical advice and consult them before making any health or treatment decisions.
